In This Section
Search/Filter
Back to Grantees
Loading...
SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team Shows that Treating CRC and PDA Patients with CXCR4 Inhibitor Effectively Elicits an Integrated Immune Response

SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team Shows that Treating CRC and PDA Patients with CXCR4 Inhibitor Effectively Elicits an Integrated Immune Response

The SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team set out in 2014 to develop immune-based therapeutic strategies for pancreatic ductal adenocarcinoma (PDA). Their efforts were spurred by the underlying hypothesis that the immunosuppressive PDA milieu could be reprogrammed into an immuno-stimulatory one capable of tumor rejection, thus converting PDA into a treatable disease.

New Club Allows AACR Grantees to Meet – Virtually

New Club Allows AACR Grantees to Meet – Virtually

As the coronavirus pandemic continues to ravage the world, conferences and meetings worldwide are being canceled or moved to virtual mode. This loss of in-person interactions has significantly reduced the number of opportunities for researchers to share ideas, present research, learn career advancement skills, and establish connections with peers, colleagues, and potential collaborators.

AACR – J&J Lung Cancer Innovative Science Grants: Cutting-Edge Approaches to Cut Down Cancer Risk

AACR – J&J Lung Cancer Innovative Science Grants: Cutting-Edge Approaches to Cut Down Cancer Risk

Lung cancer remains the number one cause of cancer-related death. This persistent dismal prognosis has been largely attributed to late-stage diagnosis, when 5-year survival rates are less than 5%. Although the potential of lung cancer screening to reduce lung cancer-related mortality has been demonstrated, there remains a need for more effective and less invasive early detection methods. The AACR-Johnson & Johnson Lung Cancer Innovative Science Grants are fueling...